3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
4
Neoplasm Metastasis
3
Rectal Neoplasms
2
Leukemia, Myeloid, Acute
2
Carcinoma, Non-Small-Cell Lung
2
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Neurofibrosarcoma
1
Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lung Neoplasms
1
Lung Cancer - Malignant Pleural Mesothelioma
1
Liver Neoplasms
1
Leukemia
1
Hematologic Neoplasms
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Esophagogastric Cancer
1
Esophageal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms, Male
1
Blast Crisis
1
Interventions
Carboplatin
41
Paclitaxel
40
pembrolizumab
38
Cyclophosphamide
23
Gemcitabine
22
130-nm albumin-bound paclitaxel
21
Doxorubicin
18
Cisplatin
18
Albumin-Bound Paclitaxel
18
atezolizumab
16
Taxes
15
Capecitabine
13
veliparib
10
Nivolumab
9
Docetaxel
9
Bevacizumab
9
olaparib
8
liposomal doxorubicin
7
Everolimus
7
spartalizumab
6
durvalumab
6
Epirubicin
6
trametinib
5
pegfilgrastim
5
eribulin
5
Irinotecan
5
Filgrastim
5
iniparib
4
binimetinib
4
apatinib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Triple Negative Breast Neoplasms
×
STA 9090
×
Clear all
NCT01677455
2015-11-05
Enchant
Synta Pharmaceuticals Corp.
Phase 2
Completed
51 enrolled